SynthesisBMC surgery2025
The impact of indocyanine green fluorescence imaging on skin flap necrosis: a systematic review and meta-analysis.
Synthesis in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSkin flap necrosis is a prevalent complication following mastectomy, significantly impacting patient recovery. Indocyanine green (ICG) fluorescence imaging offers intraoperative guidance by providing real-time evaluation of tissue perfusion; however, its efficacy in reducing postoperative necrosis remains a subject of debate. This study seeks to elucidate the impact of ICG on postoperative skin flap necrosis and the rate of reoperation through a systematic review and meta-analysis.
methodsWe systematically searched the PubMed, Embase, and Cochrane Library databases, incorporating seven retrospective cohort studies and one prospective study into our analysis. Data analysis was performed using Review Manager 5.4, this systematic review and meta-analysis was reported in accordance with the PRISMA guidelines.
resultsOur analysis included eight articles with a total of 1,252 patients who underwent mastectomy and breast flap reconstructive surgery. Our findings indicate that, compared with the control treatment, the use of indocyanine green (ICG) can significantly reduce the occurrence of skin flap necrosis (OR = 0.60; 95% CI 0.44 to 0.81; I2 = 0%; P = 0.001), severe flap necrosis (OR = 0.37; 95% CI 0.22 to 0.63; I2 = 0%; P = 0.0002), and reoperation (OR = 0.49; 95% CI 0.33 to 0.73; I2 = 28%; P = 0.0005).
conclusionsThe findings suggest that ICG can effectively reduce the risk of severe skin flap necrosis and the necessity for reoperation post-mastectomy, although its benefits for mild to moderate necrosis are limited. Future research should focus on multicenter randomized controlled trials to standardize the application of ICG and assess its feasibility in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.